NP Life Sciences Health Industry Group Inc. (ACAT)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 80K 160K 240K Q4 '19: 43K Q1 '20: 38K Q2 '20: 15K Q3 '20: 15K Q4 '20: 15K Q1 '23: 132K Q2 '23: 224.1K Q3 '23: 200.6K Q4 '23: 164.6K Q4 '19 Q2 '20 Q4 '20 Q2 '23 Q4 '23

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-180K -120K -60K 0 60K 120K 180K Q4 '19: -108.6K Q1 '20: -109K Q2 '20: -158K Q3 '20: -151.8K Q4 '20: -131.1K Q1 '21: -125.2K Q2 '21: -124.3K Q3 '21: -119.5K Q4 '21: -65.7K Q1 '22: -72.5K Q2 '22: -18.7K Q3 '22: -3.3K Q4 '22: -18.9K Q1 '23: 13.5K Q2 '23: 83.8K Q3 '23: 51.8K Q4 '23: -690 Q1 '20 Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23

Net Income TTM

-180K -120K -60K 0 60K 120K 180K Q4 '19: -108.9K Q1 '20: -109.3K Q2 '20: -158K Q3 '20: -151.7K Q4 '20: -131.1K Q1 '21: -125.2K Q2 '21: -124.3K Q3 '21: -119.5K Q4 '21: -65.7K Q1 '22: -72.5K Q2 '22: -18.7K Q3 '22: -3.3K Q4 '22: -18.9K Q1 '23: 13.5K Q2 '23: 83.6K Q3 '23: 51.3K Q4 '23: -2.9K Q1 '20 Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-150K -100K -50K 0 50K 100K 150K Q4 '19: -4.3K Q1 '20: 27.1K Q2 '20: -4.4K Q3 '20: -22.8K Q4 '20: -124.3K Q1 '21: -132.8K Q2 '21: -127.8K Q3 '21: -120K Q4 '21: -90.6K Q1 '22: -66.3K Q2 '22: -40.2K Q3 '22: -18.1K Q4 '22: 93.9K Q1 '23: 117K Q2 '23: 102.2K Q3 '23: 55.2K Q4 '23: -73.6K Q1 '20 Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23

Free Cash Flow TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Shares Outstanding Quarterly

0 15M 30M 45M Q1 '21: 43M Q2 '21: 43M Q3 '21: 43M Q1 '22: 43M Q2 '22: 43M Q3 '22: 43M Q1 '23: 43M Q2 '23: 43M Q3 '23: 43M Q1 '21 Q3 '21 Q2 '22 Q1 '23 Q3 '23

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

0.00 Q4 '19: 0.00 Q1 '20: 0.00 Q2 '20: 0.00 Q3 '20: 0.00 Q4 '20: 0.00 Q1 '21: 0.00 Q2 '21: 0.00 Q3 '21: 0.00 Q4 '21: 0.00 Q1 '22: 0.00 Q1 '20 Q3 '20 Q1 '21 Q3 '21 Q1 '22

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.